SETD2: an epigenetic modifier with tumor suppressor functionality.

Oncotarget · 2016 · PMC5226616 · PMID 27191891

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

In Tumorportal, SETD2 mutations are indicated as “highly significant” in ccRCC and glioblastoma multiform and indicated as “near significant” in bladder cancer.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.